Key facts
- This page summarizes Michael Sinclair's Form 4 filing for OPIANT PHARMACEUTICALS, INC..
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 15 Jun 2022, 16:30.
Michael Sinclair - 13 Jun 2022 Form 4 Insider Report for OPIANT PHARMACEUTICALS, INC.
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 13 Jun 2022
- Net transaction value
- -$149,188
- SEC form
- 4
- Accepted by SEC
- 15 Jun 2022, 16:30:45 UTC
- Prior SEC filing
- 13 Jun 2022
- Next SEC filing
- 03 Mar 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael Sinclair
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael Sinclair filed Form 4 for OPIANT PHARMACEUTICALS, INC. on 15 Jun 2022.
Change
- Previous filing in this sequence was filed on 13 Jun 2022.
- Current net transaction value: -$149,188.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
OPNT
transaction
Common Stock
Sale
- Transaction value
- $60,895
- Shares
- -5,491
- Change %
- -17%
- Price
- $11.09
- Shares after
- 27,345
- Date
- 13 Jun 2022
- Ownership
- Direct
OPNT
transaction
Common Stock
Sale
- Transaction value
- $78,752
- Shares
- -7,225
- Change %
- -26%
- Price
- $10.90
- Shares after
- 20,120
- Date
- 14 Jun 2022
- Ownership
- Direct
OPNT
transaction
Common Stock
Sale
- Transaction value
- $9,540
- Shares
- -900
- Change %
- -4.5%
- Price
- $10.60
- Shares after
- 19,220
- Date
- 15 Jun 2022
- Ownership
- Direct
* marks a reported price that did not pass the local price check.